$3.58
+0.08
(+2.29%)▲
Insights on Geron Corporation
Revenue is down for the last 2 quarters, 164.0K → 23.0K (in $), with an average decrease of 86.0% per quarter
Netprofit is down for the last 2 quarters, -44.80M → -51.97M (in $), with an average decrease of 16.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 8.0%
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 102.6%
1.68%
Downside
Day's Volatility :4.87%
Upside
3.25%
54.19%
Downside
52 Weeks Volatility :59.51%
Upside
11.6%
Period | Geron Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 65.74% | 2.0% | 0.0% |
6 Months | 96.7% | 11.7% | 0.0% |
1 Year | 47.93% | 5.8% | 1.3% |
3 Years | 137.09% | 14.2% | -22.1% |
Market Capitalization | 2.2B |
Book Value | $0.46 |
Earnings Per Share (EPS) | -0.32 |
PEG Ratio | -2.38 |
Wall Street Target Price | 5.08 |
Profit Margin | 0.0% |
Operating Margin TTM | -236039.14% |
Return On Assets TTM | -41.47% |
Return On Equity TTM | -112.29% |
Revenue TTM | 237.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -77.7% |
Gross Profit TTM | -93.7M |
EBITDA | -193.5M |
Diluted Eps TTM | -0.32 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.33 |
EPS Estimate Next Year | -0.17 |
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Next Quarter | -0.12 |
What analysts predicted
Upside of 41.9%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.1M | ↑ 0.09% |
Net Income | -27.0M | ↓ 3.22% |
Net Profit Margin | -2.5K% | ↑ 86.79% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 460.0K | ↓ 56.85% |
Net Income | -63.6M | ↑ 135.23% |
Net Profit Margin | -13.8K% | ↓ 11281.0% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 253.0K | ↓ 45.0% |
Net Income | -75.6M | ↑ 18.98% |
Net Profit Margin | -29.9K% | ↓ 16069.95% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.4M | ↑ 450.59% |
Net Income | -121.0M | ↑ 59.97% |
Net Profit Margin | -8.7K% | ↑ 21202.54% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 596.0K | ↓ 57.21% |
Net Income | -141.0M | ↑ 16.6% |
Net Profit Margin | -23.7K% | ↓ 14980.42% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 237.0K | ↓ 60.23% |
Net Income | -184.1M | ↑ 30.56% |
Net Profit Margin | -77.7K% | ↓ 54027.46% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 297.0K | ↑ 306.85% |
Net Income | -40.8M | ↑ 44.48% |
Net Profit Margin | -13.7K% | ↑ 24963.46% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 103.0K | ↓ 65.32% |
Net Income | -42.4M | ↑ 3.87% |
Net Profit Margin | -41.2K% | ↓ 27424.74% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.0K | ↓ 79.61% |
Net Income | -38.1M | ↓ 10.22% |
Net Profit Margin | -181.3K% | ↓ 140133.89% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 29.0K | ↑ 38.1% |
Net Income | -49.2M | ↑ 29.29% |
Net Profit Margin | -169.7K% | ↑ 11556.48% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 164.0K | ↑ 465.52% |
Net Income | -44.8M | ↓ 8.98% |
Net Profit Margin | -27.3K% | ↑ 142428.16% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 23.0K | ↓ 85.98% |
Net Income | -52.0M | ↑ 16.0% |
Net Profit Margin | -226.0K% | ↓ 198653.79% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 185.3M | ↑ 67.96% |
Total Liabilities | 7.6M | ↑ 15.88% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 165.5M | ↓ 10.67% |
Total Liabilities | 30.4M | ↑ 302.09% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 270.7M | ↑ 63.57% |
Total Liabilities | 59.8M | ↑ 96.89% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 226.0M | ↓ 16.51% |
Total Liabilities | 99.6M | ↑ 66.64% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 190.6M | ↓ 15.69% |
Total Liabilities | 110.6M | ↑ 11.0% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 394.1M | ↑ 106.78% |
Total Liabilities | 146.1M | ↑ 32.15% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 232.6M | ↓ 2.33% |
Total Liabilities | 124.4M | ↑ 29.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 190.6M | ↓ 18.07% |
Total Liabilities | 110.6M | ↓ 11.14% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 424.9M | ↑ 122.94% |
Total Liabilities | 98.8M | ↓ 10.63% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 415.3M | ↓ 2.26% |
Total Liabilities | 116.9M | ↑ 18.26% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 413.0M | ↓ 0.55% |
Total Liabilities | 122.4M | ↑ 4.74% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 394.1M | ↓ 4.59% |
Total Liabilities | 146.1M | ↑ 19.38% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.0M | ↑ 2.2% |
Investing Cash Flow | -77.7M | ↓ 438.35% |
Financing Cash Flow | 93.0M | ↑ 8267.96% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -43.8M | ↑ 108.62% |
Investing Cash Flow | 27.4M | ↓ 135.26% |
Financing Cash Flow | 19.5M | ↓ 79.03% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -66.7M | ↑ 52.07% |
Investing Cash Flow | -105.3M | ↓ 484.38% |
Financing Cash Flow | 168.3M | ↑ 763.36% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -95.6M | ↑ 43.37% |
Investing Cash Flow | 71.9M | ↓ 168.31% |
Financing Cash Flow | 48.6M | ↓ 71.16% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -127.4M | ↑ 33.3% |
Investing Cash Flow | 62.1M | ↓ 13.73% |
Financing Cash Flow | 87.3M | ↑ 79.72% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -29.6M | ↑ 3.28% |
Investing Cash Flow | 9.8M | ↑ 250.25% |
Financing Cash Flow | 4.8M | ↓ 93.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -35.2M | ↑ 18.93% |
Investing Cash Flow | 19.0M | ↑ 92.93% |
Financing Cash Flow | 11.9M | ↑ 149.54% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -46.4M | ↑ 31.79% |
Investing Cash Flow | -178.7M | ↓ 1041.29% |
Financing Cash Flow | 281.0M | ↑ 2257.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -29.6M | ↓ 36.16% |
Investing Cash Flow | -44.4M | ↓ 75.13% |
Financing Cash Flow | 18.3M | ↓ 93.47% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -50.8M | ↑ 71.75% |
Investing Cash Flow | -4.7M | ↓ 89.39% |
Financing Cash Flow | 29.4M | ↑ 60.05% |
Sell
Neutral
Buy
Geron Corporation is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Geron Corporation | 7.36% | 96.7% | 47.93% | 137.09% | 87.17% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 11.53% | 21.99% | 86.62% | 131.89% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Geron Corporation | NA | NA | -2.38 | -0.33 | -1.12 | -0.41 | NA | 0.46 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Geron Corporation | Buy | $2.2B | 87.17% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 131.89% | 28.81 | 36.68% |
RA Capital Management, LLC
BlackRock Inc
Deep Track Capital, LP
Vanguard Group Inc
State Street Corporation
Vivo Capital, LLC
Geron Corporation’s price-to-earnings ratio stands at None
Read Morewe are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Organization | Geron Corporation |
Employees | 141 |
CEO | Dr. John A. Scarlett M.D. |
Industry | Health Technology |
Dnp Select Income Closed Fund
$3.58
+2.29%
Masonite International Corp
$3.58
+2.29%
Zillow Group, Inc. - Class C Shares
$3.58
+2.29%
Edgio Inc.
$3.58
+2.29%
Papa John's International Inc.
$3.58
+2.29%
Jpmorgan Betabuilders Europe Etf
$3.58
+2.29%
Marqeta, Inc.
$3.58
+2.29%
Endeavor Group Holdings, Inc.
$3.58
+2.29%
Global X Nasdaq 100 Covered Call Etf
$3.58
+2.29%